|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:CEO
|
gptkb:Deborah_Dunsire
|
|
gptkbp:country
|
gptkb:Denmark
|
|
gptkbp:focus
|
central nervous system disorders
|
|
gptkbp:founded
|
1915
|
|
gptkbp:founder
|
gptkb:Hans_Lundbeck
|
|
gptkbp:fullName
|
gptkb:H._Lundbeck_A/S
|
|
gptkbp:headquartersLocation
|
gptkb:Copenhagen,_Denmark
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Lundbeck
|
|
gptkbp:industry
|
pharmaceuticals
|
|
gptkbp:ISIN
|
DK0010287234
|
|
gptkbp:logo
|
Lundbeck logo.svg
|
|
gptkbp:memberState
|
more than 50
|
|
gptkbp:notableProduct
|
gptkb:Brintellix
gptkb:Cipralex
gptkb:Abilify_Maintena
gptkb:Northera
gptkb:Sabril
|
|
gptkbp:numberOfEmployees
|
~5,600
|
|
gptkbp:parentOrganization
|
gptkb:Lundbeck_Foundation
|
|
gptkbp:products
|
antipsychotics
antidepressants
antiepileptics
Parkinson's disease treatments
Alzheimer's disease treatments
|
|
gptkbp:researchInterest
|
gptkb:Alzheimer's_disease
gptkb:Parkinson's_disease
gptkb:depression
epilepsy
schizophrenia
migraine
|
|
gptkbp:revenue
|
DKK 17.7 billion (2022)
|
|
gptkbp:servesArea
|
worldwide
|
|
gptkbp:stockExchange
|
gptkb:Nasdaq_Copenhagen
|
|
gptkbp:stockSymbol
|
gptkb:LUN
|
|
gptkbp:subsidiary
|
gptkb:Lundbeck_Foundation
|
|
gptkbp:type
|
gptkb:public_company
|
|
gptkbp:website
|
https://www.lundbeck.com/
|
|
gptkbp:bfsParent
|
gptkb:citalopram
gptkb:Grete_Lundbeck
gptkb:PhRMA
|
|
gptkbp:bfsLayer
|
6
|